199 related articles for article (PubMed ID: 32356477)
1. Nothing is perfect: the safety issues of integrase inhibitor regimens.
Scévola S; Tiraboschi JM; Podzamczer D
Expert Opin Drug Saf; 2020 Jun; 19(6):683-694. PubMed ID: 32356477
[TBL] [Abstract][Full Text] [Related]
2. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
Lin KY; Sun HY; Yang CJ; Lu PL; Lee YT; Lee NY; Liou BH; Tang HJ; Lee MH; Wang NC; Chen TC; Hii IM; Huang SH; Lin CY; Tsai CS; Cheng CY; Hung CC;
Clin Infect Dis; 2024 May; 78(5):1295-1303. PubMed ID: 38051646
[TBL] [Abstract][Full Text] [Related]
3. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
Wilson HI; Mapesi H
Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
[No Abstract] [Full Text] [Related]
4. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect.
Yombi JC
AIDS Rev; 2018; 20(1):14-26. PubMed ID: 29628511
[TBL] [Abstract][Full Text] [Related]
7. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low- and Middle-Income Countries After Initial Concerns About Teratogenicity : An Observational Study.
Romo ML; Patel RC; Edwards JK; Humphrey JM; Musick BS; Bernard C; Maina MW; Brazier E; Castelnuovo B; Penner J; Wyka K; Cardoso SW; Ly PS; Kunzekwenyika C; Cortés CP; Panczak R; Kelvin EA; Wools-Kaloustian KK; Nash D;
Ann Intern Med; 2022 Jan; 175(1):84-94. PubMed ID: 34843382
[TBL] [Abstract][Full Text] [Related]
10. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
Abo YN; Refsum E; Mackie N; Lyall H; Tudor-Williams G; Foster C
Clin Drug Investig; 2019 Jun; 39(6):585-590. PubMed ID: 30976998
[TBL] [Abstract][Full Text] [Related]
11. Investigational HIV integrase inhibitors in phase I and phase II clinical trials.
Han Y; Mesplède T; Wainberg MA
Expert Opin Investig Drugs; 2017 Nov; 26(11):1207-1213. PubMed ID: 28956664
[TBL] [Abstract][Full Text] [Related]
12. Weight gain and integrase inhibitors.
Eckard AR; McComsey GA
Curr Opin Infect Dis; 2020 Feb; 33(1):10-19. PubMed ID: 31789693
[TBL] [Abstract][Full Text] [Related]
13. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety.
Scarsi KK; Havens JP; Podany AT; Avedissian SN; Fletcher CV
Drugs; 2020 Nov; 80(16):1649-1676. PubMed ID: 32860583
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
Rolle CP; Castano J; Nguyen V; Patel K; Hinestrosa F; DeJesus E
Antivir Ther; 2023 Feb; 28(2):13596535231163703. PubMed ID: 36896821
[TBL] [Abstract][Full Text] [Related]
17. Tolerability of HIV integrase inhibitors.
Lee FJ; Carr A
Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
[TBL] [Abstract][Full Text] [Related]
18. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
19. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
[No Abstract] [Full Text] [Related]
20. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
Engelman AN; Cherepanov P
FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
